Christopher J. Senner
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Christopher J. Senner
Earlier roles on record: Board Member at Quince Therapeutics, Inc. (QNCX) until October 2, 2026. Quince Therapeutics, Inc. reported in an 8-K filed October 9, 2026 that Christopher J. Senner resigned as director, effective October 8, 2026. Quince Therapeutics, Inc. reported in an 8-K filed October 2, 2026 that Christopher J. Senner resigned as Director.
“As previously announced, effective as of October 8, 2026, June Bray, David Lamond, Christopher Senner, and Mr. Thye resigned from the Board.”
“On September 30, 2026, each of June Bray, David Lamond and Christopher Senner (collectively, the “Resigning Directors”) tendered conditional resignations from the Board of Directors (the “Board”) of Quince Therapeutics, Inc. (the “Company”), in each case effective as of two business days following the conclusion of the Company’s Special Meeting of Stockholders, which will be held on October 6, 2026 (the “Special Meeting”), and contingent upon the approval by the Company’s stockholders of the following three proposals to be presented at the Special Meeting (the “Effective Time”)”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
2019-01-01–2026-10-02
Company network
Recorded roles and call appearances connecting this person to public companies.
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.